FDNA Expands Leadership Team with Addition of Chief Medical Officer and Chief Data Science Officer

April 9, 2018

BioSpace

“FDNA, developer of the Face2Gene suite of next-generation phenotyping (NGP) applications, announces at the American College of Medical Genetics and Genomics annual meeting the appointment of Dr. Karen Gripp to Chief Medical Officer and Dr. Peter Krawitz to Chief Data Science Officer. With this expansion in leadership, FDNA continues to strengthen its position as a global leader in using artificial intelligence to promote precision medicine.”

 

The article announces the expansion of FDNA’s leadership team with the appointment of a new Chief Medical Officer and Chief Data Science Officer. These strategic hires aim to bolster FDNA’s expertise in deep phenotyping, a cutting-edge approach that leverages AI to analyze detailed phenotypic data. This enhanced leadership is expected to accelerate the development of FDNA’s innovative technologies, improving the accuracy and speed of expediting the diagnosing of rare genetic disorders. FDNA’s commitment to deep phenotyping highlights its leadership in personalized medicine and genomic research.

Related articles

Dr. Bruno

The Importance of Teaching Face2Gene to Pediatricians

In the world of rare genetic diseases, early diagnosis is often the key to better patient outcomes. However, the diagnostic journey can be long and complex, sometimes taking years before a definitive answer is found. Dr. Bruno Bordest, a Brazilian geneticist who teaches at the Universidade Federal de Mato Grosso, has been working to bridge […]

Continue reading
AI in genetic diagnosis

The Evolution of FDNA’s technology: An Interview with Aviram Bar Haim

Analyzing facial features has long been a vital step in diagnosing genetic syndromes. In recent years, AI-driven technologies have transformed this process, making it more efficient and accurate. Leading this innovation is Face2Gene, an advanced AI platform that leverages machine learning to assist clinicians in identifying genetic disorders. To explore the development of this groundbreaking […]

Continue reading